chevron_leftBack
As of 24 April 2025, MoonLake Immunotherapeutics has a market cap of $2.5B USD, ranking #4614 globally and #85 in Switzerland. It ranks #412 in the Healthcare sector, and #97 in the Biotechnology industry.
Key Stats
Market Cap
$2.5BUSD
Enterprise Value
$2.06BUSD
EBITDA (TTM)
-$141.71MUSD
Net Income (TTM)
-$118.94MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jorge da Silva
open_in_new
Employees
100
Founded
2021
Website
moonlaketx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.2% | 7.1% | -1.3% | -16% | -18% | -3.5% |
Upcoming Earnings
Earnings Date
Tue, May 6
Earnings Time
sunny
Before Open
EPS Estimate
-$0.6200
Revenue Estimate
-
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
MLTX
MoonLake Immunotherapeutics Class A
ISIN: KY61559X1045
Shares Out.:
Shares Outstanding:
63.283M1
Shares Float:
52.779M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
39.51 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
